The combination of a strong earnings beat, raised guidance, and a strategically transformative acquisition positions AMRX for accelerated growth in biosimilars. Traders should monitor the shareholder vote and regulatory approvals for the Kashiv deal, and watch for further pipeline updates. The stock's reaction will likely focus on the long-term synergy potential and execution risk.
Price Chart
Executive Summary
Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY growth) and adjusted diluted EPS of $0.27, a 29% increase YoY and 59% above consensus of $0.17. The company raised full-year 2026 adjusted EPS guidance and announced a transformative $750M acquisition of Kashiv BioSciences to establish a leading biosimilars platform, positioning it to capture value from the upcoming $300B+ biologics LOE wave.
Key Financial Metrics
Key Facts
- Preliminary Q1 2026 revenue: $723M (4% YoY growth)
- Adjusted diluted EPS: $0.27 vs. consensus of $0.17 (59% beat)
- GAAP diluted EPS: $0.19, also above consensus
- Specialty segment revenue up 23% YoY to $133M driven by CREXONT® and BREKIYA®
- Gross margin expanded 750 bps to 44.3% on strong product mix
- Announced acquisition of Kashiv BioSciences for $750M ($375M cash + $375M equity) plus up to $350M in milestones
- Raised 2026 full-year adjusted EPS guidance to $0.95–$1.05 (from $0.93–$1.03), now above consensus of $0.90)
- Transaction expected to close in second half of 2026, subject to shareholder and regulatory approval
Financial Impact
Adjusted EPS of $0.27 beats consensus by $0.10 (59%), revenue of $723M beats by $2.5M. Full-year adjusted EPS guidance raised and now above consensus. Acquisition adds $400M–$500M in expected synergies.
Risk Factors
- Acquisition requires shareholder and regulatory approvals, creating execution risk
- Preliminary financials are subject to change upon final audit
- Integration risk from combining Kashiv’s operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278749 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K/A | $21.02 | awaiting T+60 | — | $21.02 (+0.00%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.02 (+4.27%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.02 (−15.81%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.02 (+22.92%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.02 (+13.62%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.02 (+17.76%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers